Physician-researchers at City of Hope have developed a new system to engineer T cells in order to overcome resistance to CAR T cell therapy. The system involves using a dual-vector approach to increase the genetic information capacity, allowing for the simultaneous targeting of multiple antigens and the incorporation of switch receptors. This approach has shown improved anti-tumor activity in mouse models and holds promise for clinical translation. The researchers believe that this platform, named “zip-sorting,” could be used to enhance the efficacy of CAR T cell therapies by allowing T cells to resist multiple evasion strategies at once.
Source link
Engineered T cells could help patients overcome resistance to CAR T cell therapy
